Overview
BD OMICS-One™ WTA Next Assayは、卓越した感度とバイアスのない全トランスクリプトーム解析により、シングルセルRNAシーケンスの新しい基準を確立します。BD Rhapsody™ シングルセル解析システム上で、RNA-seqの単独ワークフローはもちろん、CITE-seq、ATAC-seq、免疫レパートリー解析との統合にも対応し、高い再現性を実現します。この新しいアッセイは、すべてのマルチオミクスアプリケーションにおいて一貫した高品質な結果を提供。8レーンカートリッジで、1レーンあたり1,000～100,000細胞の入力範囲に対応します。
BD OMICS-One™ WTA Next Assay のカタログ> をダウンロード
BD Rhapsody™ システムへの組み込み方法は プロトコールページ をご参照ください。
Features
卓越した感度、強化されたマルチオミクス機能、柔軟性の向上、信頼性の高いスケーラビリティ、そして優れたコストパフォーマンスを提供します。さらに、このアッセイはクラス最高レベルの感度を実現し、希少なトランスクリプトや細胞の複雑性をすべての対応ワークフローで明らかにします。主要な指標において、10x Genomics社のChromium GEM-X Single Cell 3' v4 Gene Expression Assayを上回る性能を発揮します。
1細胞あたり3,000以上の遺伝子検出
| スケーラブルなスループット
|
マルチオミクス性能の強化
| サンプルあたりのコスト削減
|
F柔軟なサンプル処理 |
Performance
Head-to-head comparison of the BD OMICS-One™ WTA Next Assay versus the 10x Genomics Chromium GEM-X Single Cell 3' v4 Gene Expression Assay using matched PBMC samples from three donors processed under identical conditions.
Bar graphs show median UMIs (A) and median genes per cell (B) at 25,000 and 50,000 raw sequencing reads per cell. The BD OMICS-One™ WTA Next Assay achieves higher molecular and gene detection that becomes increasingly more pronounced as sequencing depth increases, demonstrating best-in-class sensitivity for single-cell RNA sequencing applications. Error bars represent standard deviation across three biological replicates.
Performance comparison of the new BD OMICS-One™ WTA Next Assay (WTA Next) versus the current BD Rhapsody™ Whole Transcriptome Analysis (WTA) Assay using previously frozen PBMC samples from three healthy matched donors processed in standalone WTA experiments.
(A) Median number of unique molecular identifiers (UMIs) per cell as a function of raw sequencing reads per cell, demonstrating a 120% increase in transcript detection with WTA Next at 50,000 reads per cell.
(B) Median number of genes detected per cell across varying sequencing depths, showing a 67% improvement with WTA Next at 50,000 reads per cell. Error bars represent standard deviation across three biological replicates. .WTA workflow: 20,000 cells targeted with ~16,000 recovered, subsampled to 4,000 for analysis. WTA Next workflow: 40,000 cells targeted with ~30,000 recovered, subsampled to 3,000 cells. All captures were performed on a BD Rhapsody™ 8-Lane Cartridge.
Gene recovery comparison between the current BD Rhapsody™ Whole Transcriptome Analysis (WTA) Assay and new BD OMICS-One™ WTA Next Assay (WTA Next) across different multiomics applications.
(A) Cell-based workflows using frozen PBMCs. Left: CITE-seq showing 38% increase in median genes per cell with WTA Next at ~23,000 reads per cell. Right: TCR/BCR-based assay demonstrating 81% improvement with WTA Next at ~22,700 reads per cell.
(B) Nuclei-based workflows using fresh PBMCs. Left: ATAC-seq showing 156% increase in median genes per cell with WTA Next at 25,000 reads per cell. Right: Multiplexed ATAC-seq demonstrating 126% improvement with WTA Next at 25,000 reads per cell. The BD OMICS-One™ WTA Next Assay delivers substantial performance gains across all supported multiomic combinations, either in single-cell or nuclei-based implementations.
Reproducibility assessment with two independent users processing the same frozen PBMC sample from one donor in separate experiments (with 30,000 cells).
(A) Bar graphs show nearly identical median UMIs (left) and median genes (right) per cell at 25,000 reads per cell, confirming consistent sensitivity across users.
(B) Gene expression correlation (R2 = 1.0) demonstrating exceptional inter-user reproducibility, confirming robust assay performance independent of operator variability. Consistent results across users ensure reliable data generation in multi-operator laboratories and collaborative research settings.
Applications
BD OMICS-One™ WTA Next Assayの高感度とバイアスのないプロファイリングにより、免疫学、腫瘍学、神経科学、発生生物学、創薬の分野で革新的な発見を可能にします。
Identification and resolution of distinct immune cell populations in PBMC samples
Gene expression distributions across immune cell types
Immune profiling ability to resolve functional subpopulations within major cell types
Frequently Asked Questions
Download our FAQ document if you have more in-depth questions>
- How does the performance of the new BD OMICS-One™ WTA Next Assay compare to the current BD Rhapsody™ Whole Transcriptome Analysis (WTA) Assay? The BD OMICS-One™ WTA Next Assay delivers significant improvements in molecule and gene recovery. We observed an average 120% and 67% increase in molecule and gene detection, respectively, across three PBMC donors at 50,000 reads per cell.
- How does the performance of multiomic assays compare to assays run on the BD Rhapsody™ WTA Assay? The BD OMICS-One™ WTA Next Assay enhances gene recovery across all multiomics workflows. Improvements are workflow-dependent, ranging from ~40% increase with CITE-seq to ~155% with ATAC-seq at 25,000 reads per cell.
- How does the BD OMICS-One™ WTA Next Assay compare to the 10x Genomics GEM-X v4 Assay? BD OMICS-One™ WTA Next Assay exceeds GEM-X assay across key metrics. In head-to-head comparisons, we recovered ~5% more genes per cell at 50,000 reads per cell, delivering unmatched performance in single-cell RNA-seq analysis.
- What are the key differences between the BD OMICS-One™ WTA Next Assay and BD Rhapsody™ WTA Assay workflows? The BD OMICS-One™ WTA Next Assay features optimized reagents and refined processing steps that enhance sensitivity without changing the fundamental workflow. Contact our Support team for detailed protocol comparisons specific to your application.
- Can I use my existing protocols? No. The BD OMICS-One™ WTA Next Assay, for the most part, maintains the same workflow as the BD Rhapsody™ WTA Assay with identical hands-on time and processing steps but you must use the updated protocols.
- Is the BD OMICS-One™ WTA Next Assay compatible with BD® Single-Cell Multiplexing Kits, BD® AbSeq Antibody-Oligos and BD Rhapsody™ ATAC-Seq and TCR/BCR Next Assays? Absolutely. The BD OMICS-One™ WTA Next Assay maintains full compatibility while delivering enhanced gene expression performance across all supported multiomics workflows.
- Is the BD OMICS-One™ WTA Next Assay more cost-effective than the BD Rhapsody™ WTA Assay? Yes, the BD OMICS-One™ WTA Next Assay reduces per-sample costs by up to 10% compared to the BD Rhapsody™ WTA Assay despite enhanced performance.
- Can I store samples before processing? Yes. In addition to fresh processing, you can store your samples at 4 °C for up to 72 hours in BD® OMICS-Guard Sample Preservation Buffer or cryopreserve them for long-term storage with our cryopreservation solution.
- How many cells can I process? You can load up to 100,000 cells per lane on our 8-lane cartridge and capture 80%+ of 800,000 cells per full cartridge run.
- Will the BD Rhapsody™ WTA Assay remain available once the BD OMICS-One™ WTA Next Assay is launched? The main amplification kit for the BD Rhapsody™ WTA Assay (Cat. No. 633801) will phase out as the BD OMICS-One™ WTA Next Assay kit becomes available. We recommend transitioning to the BD OMICS-One™ WTA Next Assay for superior performance and economics.
-
Brochure
-
Datasheets
-
FAQs
本製品は研究用です。疾病の診断・治療または予防に使用することはできません。